ES2389958T3 - Uso de derivados de quinolina en el tratamiento del dolor - Google Patents

Uso de derivados de quinolina en el tratamiento del dolor Download PDF

Info

Publication number
ES2389958T3
ES2389958T3 ES08718011T ES08718011T ES2389958T3 ES 2389958 T3 ES2389958 T3 ES 2389958T3 ES 08718011 T ES08718011 T ES 08718011T ES 08718011 T ES08718011 T ES 08718011T ES 2389958 T3 ES2389958 T3 ES 2389958T3
Authority
ES
Spain
Prior art keywords
pain
compound
treatment
pharmaceutically acceptable
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08718011T
Other languages
English (en)
Spanish (es)
Inventor
Gordon Bruton
Barry Sidney Orlek
Geoffrey Stemp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0705424A external-priority patent/GB0705424D0/en
Priority claimed from GB0712390A external-priority patent/GB0712390D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2389958T3 publication Critical patent/ES2389958T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
ES08718011T 2007-03-21 2008-03-19 Uso de derivados de quinolina en el tratamiento del dolor Active ES2389958T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0705424A GB0705424D0 (en) 2007-03-21 2007-03-21 Use of compounds in the treatment of pain and irritable bowel syndrome
GB0705424 2007-03-21
GB0712390A GB0712390D0 (en) 2007-06-26 2007-06-26 Use of compounds in the treatment of pain and irritable bowel syndrome
GB0712390 2007-06-26
PCT/EP2008/053285 WO2008113818A1 (en) 2007-03-21 2008-03-19 Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome

Publications (1)

Publication Number Publication Date
ES2389958T3 true ES2389958T3 (es) 2012-11-05

Family

ID=39564633

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08718011T Active ES2389958T3 (es) 2007-03-21 2008-03-19 Uso de derivados de quinolina en el tratamiento del dolor

Country Status (5)

Country Link
US (1) US20100041672A1 (cg-RX-API-DMAC7.html)
EP (1) EP2120950B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010521516A (cg-RX-API-DMAC7.html)
ES (1) ES2389958T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008113818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AU2008231787A1 (en) 2007-03-23 2008-10-02 Abbott Gmbh & Co. Kg Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP3718547A1 (en) 2011-10-03 2020-10-07 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2014165701A1 (en) * 2013-04-03 2014-10-09 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
AU2013229854B2 (en) * 2012-03-08 2017-08-17 Spr Therapeutics, Inc. System and method for treatment of pain related to limb joint replacement surgery
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
WO2017134280A1 (en) * 2016-02-05 2017-08-10 Pharnext Novel combinatorial therapies of neurological disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596001A (en) * 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
US5576338A (en) * 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US20010051719A1 (en) * 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
AU757059B2 (en) * 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
CN1087294C (zh) * 1997-07-11 2002-07-10 史密丝克莱恩比彻姆有限公司 新化合物
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6403808B1 (en) * 1999-12-10 2002-06-11 Virginia Commonwealth University Selective 5-HT6 receptor ligands
US6310212B1 (en) * 2000-03-28 2001-10-30 Neurogen Corporation 4-substituted quinoline derivatives
GB0021450D0 (en) * 2000-08-31 2000-10-18 Smithkline Beecham Plc Novel compounds
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
DE10053813A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung von Sulfonamiden
US6849644B2 (en) * 2000-11-21 2005-02-01 Smithkline Beecham P.L.C. Isoquinoline derivatives useful in the treatment of CNS disorders
ES2271124T3 (es) * 2000-11-24 2007-04-16 Smithkline Beecham Plc Compuestos indolil-sulfonilicos utiles en el tratamiento de trastornos del snc.
MXPA03011244A (es) * 2001-06-07 2004-02-27 Hoffmann La Roche Nuevos derivados de indol con afinidad por el receptor 5-ht6.
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
JP2005518414A (ja) * 2001-12-21 2005-06-23 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用
WO2003065046A2 (en) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
ATE323680T1 (de) * 2002-02-13 2006-05-15 Glaxo Group Ltd 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
US7452888B2 (en) * 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
BR0316962A (pt) * 2002-12-03 2005-10-25 Hoffmann La Roche Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc
AU2004213375A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
GB0322629D0 (en) * 2003-09-26 2003-10-29 Glaxo Group Ltd Novel compound
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
ES2317244T3 (es) * 2004-06-09 2009-04-16 Glaxo Group Limited Derivados de pirrolopiridina.
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands

Also Published As

Publication number Publication date
WO2008113818A1 (en) 2008-09-25
US20100041672A1 (en) 2010-02-18
EP2120950A1 (en) 2009-11-25
EP2120950B1 (en) 2012-07-04
JP2010521516A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
ES2389958T3 (es) Uso de derivados de quinolina en el tratamiento del dolor
ES2920681T3 (es) Compuestos
JP6732855B2 (ja) 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体
ES2219813T3 (es) N-(1-nbutil-4-piperidinil)metil-3,4-dihidro-2h-1,3-oxazino-3,2-a-indol-10-carboxamida, o una de sus sales farmaceuticamente aceptables.
ES2236185T3 (es) Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o neuropatico y migrañas.
ES2612471T3 (es) Antagonistas D2, métodos de síntesis y métodos de uso
ES2743402T3 (es) Derivados de amidas como bloqueadores TTX-S
ES2718550T3 (es) Análogos de urea con puente sustituidos como moduladores de sirtuinas
TW201242965A (en) Ring-fused heterocyclic derivative
ES2986581T3 (es) Antagonistas del receptor muscarínico de acetilcolina M4
TW200831476A (en) Cyclic sulfonamide derivatives and methods of their use
WO2013151938A1 (en) Methods for improving diaphragm function
JP7352294B2 (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
TW201231052A (en) 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
TW200902000A (en) Piperidinones useful in the treatment of inflammation
ES2683703T3 (es) Derivados de 6-aminopiridina-3-ol o sales farmacéuticamente aceptables del mismo y composición farmacéutica que los contiene como principios activos para prevenir o tratar enfermedades provocadas por angiogénesis
BR112019020798A2 (pt) métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
CA2977444A1 (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
ES2770047T3 (es) Compuestos de azetidiniloxifenilpirrolidina
CN116854693A (zh) P2x3和/或p2x2/3化合物及方法
EP2760450A1 (en) Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
BR112019022553A2 (pt) novo derivado de tetrahidronaftil ureia
ES2895904T3 (es) Tetrahidroindazoles y usos médicos de los mismos
ES2918948T3 (es) Sustancia polimórfica de hidrocloruro de yonkenafil, método de preparación de la misma y composición y uso de la misma
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물